The stock price of FibroGen Inc (NASDAQ: FGEN) has jumped by 0.03 compared to previous close of 0.31. Despite this, the company has seen a gain of 1.31% in its stock price over the last five trading days. globenewswire.com reported 2025-06-09 that SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
Is It Worth Investing in FibroGen Inc (NASDAQ: FGEN) Right Now?
The stock has a 36-month beta value of 0.82. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for FGEN is 94.08M, and at present, short sellers hold a 3.95% of that float. On June 12, 2025, the average trading volume of FGEN was 935.12K shares.
FGEN’s Market Performance
FGEN stock saw an increase of 1.31% in the past week, with a monthly gain of 3.27% and a quarterly increase of -27.63%. The volatility ratio for the week is 2.66%, and the volatility levels for the last 30 days are 3.65% for FibroGen Inc (FGEN). The simple moving average for the last 20 days is -1.35% for FGEN’s stock, with a simple moving average of -20.88% for the last 200 days.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at 1.08% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.80% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Wettig Thane, who purchase 145,000 shares at the price of $0.35 back on Mar 24 ’25. After this action, Wettig Thane now owns 543,329 shares of FibroGen Inc, valued at $50,663 using the latest closing price.
Schoeneck James A, the Director of FibroGen Inc, purchase 250,000 shares at $0.35 during a trade that took place back on Mar 20 ’25, which means that Schoeneck James A is holding 323,722 shares at $88,000 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- 5.7 for the present operating margin
- 0.58 for the gross margin
The net margin for FibroGen Inc stands at 0.43. The total capital return value is set at -1.46.
Currently, EBITDA for the company is -142.43 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 0.1. The receivables turnover for the company is -160.16for trailing twelve months and the total asset turnover is -0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
To sum up, FibroGen Inc (FGEN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
